When chemists design drug candidates, shape matters enormously. Many active pharmaceutical ingredients contain branched carbon structures—points where the molecular chain forks in a specific direction—that are critical to whether a molecule will bind to its biological target and whether it will be safe. The challenge is that the branched building blocks used to create these structures are not very abundant or commercially available. Now, scientists at Scripps Research have devised a new approach to building these branched molecular structures found in many medicines and materials: one that could make the early stages of drug discovery faster and more efficient.
The method, published in Science, overcomes a stubborn technical obstacle that has limited chemists’ ability to assemble complex molecules from simple, inexpensive starting materials.
“This work solves a selectivity problem that challenged us for years,” says Ryan Shenvi, professor at Scripps Research and senior author of the study. “We’ve now laid the groundwork to access iteratively branching materials that occur in metabolites, fragrances and drugs.”
